Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)

The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.

Study Overview

• Status: Not yet recruiting
• Conditions: Methamphetamine Abuse

Detailed Description

This is a pilot study that examines previously undiagnosed cardiac pathology utilizing transthoracic echocardiogram (TTE) in pregnant women with chronic methamphetamine use and assesses possible screening modalities (cardiac point-of-care ultrasound (POCUS), serum biomarkers, electrocardiogram (EKG)) in identifying underlying disease in this population. As this is a prospective observational study, we will assess pregnancy-related complications and care connections in the pilot tertiary academic setting.

• Study Type: Observational
• Enrollment (Estimated): 35

Contacts and Locations

• Study Contact: Name: Evan Shalen, MD; Phone Number: 503-494-1775; Email: shalen@ohsu.edu
• Study Contact Backup: Name: Sara McCrimmon; Email: mccrimmo@ohsu.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Pregnant women > or equal to 20 weeks gestation presenting to OHSU for hospital, day patient, or observation admission will be identified via the electronic medical record.

Description

Inclusion Criteria:

• 18 years or older > 20 weeks gestation admitted to the hospital
• Active patient-defined regular methamphetamine use for at least 1 year and any use within the last month
• Able to understand and provide informed consent
• Able to understand English

Exclusion Criteria:

These criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.

• Prescribed stimulants
• Echocardiogram or EKG previously performed during current pregnancy
• Previous diagnosis of congestive heart dysfunction
• Previous diagnosis of pulmonary hypertension
• Previous myocardial infarction
• Previous diagnosis of endocarditis
• Prior cardiac intervention (repair of cardiac congenital lesion, valve replacement or repairs, percutaneous/operative treatment of arrhythmias)
• High-risk aortopathy (Marfan syndrome, bicuspid aortopathy, prior aortic dissection)

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity of point of care cardiac ultrasound for the detection of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram.	This outcome seeks to identify the sensitivity of point of care cardiac ultrasound for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine when performed by an obstetrics provider, as compared to formal transthoracic echocardiogram.	Day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pregnancy and delivery outcomes in people who use methamphetamine	This outcome seeks to identify the prevalence of pregnancy delivery complications in people who use methamphetamine.	3 months postpartum
Changes to pregnancy-related treatment plan based on cardiovascular screening in people who use methamphetamine.	This outcome seeks to identify linkage to cardiovascular and addiction specialty care among patients diagnosed with cardiovascular disease.	3 months postpartum
Sensitivity of cardiac biomarkers and ECG for the identification of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram. methamphetamine	This outcome seeks to identify the sensitivity of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity troponin and electrocardiogram for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine, as compared to formal transthoracic echocardiogram.	Day 1
Prevalence of underlying structural heart disease in pregnant people who use methamphetamine	This outcome seeks to identify the prevalence of structural heart disease in pregnant people who use methamphetamine.	Day 1

Collaborators and Investigators

• Sponsor: Oregon Health and Science University

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: December 16, 2025
• First Submitted That Met QC Criteria: December 16, 2025
• First Posted (Estimated): December 30, 2025

Study Record Updates

• Last Update Posted (Estimated): January 2, 2026
• Last Update Submitted That Met QC Criteria: December 29, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Pregnancy; Cardiomyopathy; Methamphetamine use
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Cardiomyopathies
• Other Study ID Numbers: STUDY00028946

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No